在接受Prochlorperazine的儿科患者中,二胺和偏头痛治疗失败
Sobia Naeem1, Juan M Lozano2, Ana Maria Ruiz Castaneda1
1From the Department of Pediatric Emergency Medicine, Nicklaus Children's Hospital.
Pediatric emergency care
|May 8, 2024
概括
添加diphenhydramine用于治疗儿科偏头痛的普洛克洛普拉治疗并没有增加治疗失败. 当二胺与外皮拉米德一起使用时,也没有观察到外皮拉米德的副作用.
科学领域:
- 儿科急救医学 儿科急救医学
- 临床药理学 临床药理学
- 神经学 神经学
背景情况:
- 在儿童中,偏头痛的治疗往往涉及抗药物,如前.
- 使用二胺与前甲是常见的,以减轻额外皮拉米德的副作用,但其对偏头痛治疗疗效的影响不太清楚.
研究的目的:
- 为了评估是否同时使用芬胺和普洛克洛普拉对儿科患者的偏头痛治疗失败产生影响.
- 为了比较单独的普罗克洛普拉和与二胺合的普罗克洛普拉之间的额外皮拉米德不良反应的发生率.
主要方法:
- 对1683名年龄在7-18岁的患者进行了回顾性队列研究,这些患者在急诊室接受了偏头痛治疗.
- 分析对比了接受前甲素与或没有二胺胺的患者之间的结果 (额外治疗,住院治疗,72小时后返回) 和额外皮拉米德的不良反应.
- 使用多变量逻辑回归来调整潜在的混因素.
主要成果:
- 双胺联合使用与增加对额外治疗的需求 (aOR 0.74),住院率 (aOR 1.22) 或72小时回归率 (aOR 0.91) 之间没有发现显著的关联.
- 外皮拉米德的不良反应报告在2.4%的接受单独普洛克洛普拉的患者中,而在那些接受普洛克洛普拉和二胺的人中为0%.
结论:
- 双胺与前烯的同时使用似乎不会增加儿科患者偏头痛治疗失败的风险.
- 在这个队列中,二氨酸的同时使用与缺乏外皮拉米德效应有关.
相关概念视频
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
268
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
268
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
197
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
197
01:24Parkinson's Disease: Treatment
263
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
263
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
159
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
159
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
309
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
309
01:26Cholinergic Antagonists: Therapeutic Uses
742
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
742